The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jourWhich countries will have an Ebola case in 2026?
Which countries will have an Ebola case in 2026?
$23,592 Vol.
31 déc. 2026
South Sudan
80%
Rwanda
55%
Burundi
47%
United States
32%
Canada
28%
Kenya
53%
India
35%
Republic of the Congo
25%
Nigeria
47%
Ethiopia
50%
Somalia
25%
China
30%
$23,592 Vol.
South Sudan
$641 Vol.
80%
Rwanda
$448 Vol.
55%
Burundi
$200 Vol.
47%
United States
$7,118 Vol.
32%
Canada
$839 Vol.
28%
Kenya
$141 Vol.
53%
India
$539 Vol.
35%
Republic of the Congo
$9,318 Vol.
25%
Nigeria
$24 Vol.
47%
Ethiopia
$64 Vol.
50%
Somalia
$70 Vol.
25%
China
$2,236 Vol.
30%
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Marché ouvert : May 22, 2026, 12:35 PM ET
Volume
$23,592Date de fin
31 déc. 2026Marché ouvert
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
This market will resolve to "Yes" if there is a confirmed case of Ebola in the territory of the specified country reported between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Any active laboratory-confirmed, or otherwise officially confirmed, Ebola infection identified within the territory of the specified country will qualify, regardless of where exposure, symptom onset, or testing occurred.
The primary resolution sources for this market will be official information from the relevant national and international health authorities; however, an overwhelming consensus of credible reporting will also suffice.
Volume
$23,592Date de fin
31 déc. 2026Marché ouvert
May 22, 2026, 12:35 PM ETResolver
0x65070BE91...The ongoing Bundibugyo virus Ebola outbreak, declared a PHEIC by WHO in May 2026, drives market sentiment, with DRC reporting 837 confirmed cases and 196 deaths as of mid-June per CDC and ECDC data, plus 19 confirmed cases in Uganda. This marks the largest known outbreak of this strain, fueled by a likely February spillover, remote locations in Ituri and neighboring provinces, armed conflict, population displacement, and weak surveillance that delays detection and isolation. CDC models project potential growth to thousands of cases without improved containment, while low U.S. risk reflects limited international travel links and screening measures. Key upcoming factors include updated WHO/Africa CDC situation reports, revised transmission models, and any new cross-border detections that could expand the list of affected countries before year-end.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes